ACHILLION PHARMACEUTICALS IN's ticker is ACHN and the CUSIP is 00448Q201. A total of 154 filers reported holding ACHILLION PHARMACEUTICALS IN in Q1 2016. The put-call ratio across all filers is 0.20 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $103,000 | +139.5% | 17,059 | +42.7% | 0.00% | – |
| Q3 2019 | $43,000 | +43.3% | 11,955 | +6.3% | 0.00% | – |
| Q2 2019 | $30,000 | +900.0% | 11,250 | +506.5% | 0.00% | – |
| Q4 2018 | $3,000 | 0.0% | 1,855 | +98.4% | 0.00% | – |
| Q3 2018 | $3,000 | 0.0% | 935 | -2.9% | 0.00% | – |
| Q2 2018 | $3,000 | +200.0% | 963 | +124.0% | 0.00% | – |
| Q4 2017 | $1,000 | -94.4% | 430 | -89.6% | 0.00% | – |
| Q3 2017 | $18,000 | -93.1% | 4,118 | -92.7% | 0.00% | – |
| Q2 2017 | $260,000 | +16.1% | 56,715 | +6.4% | 0.00% | – |
| Q1 2017 | $224,000 | +11100.0% | 53,305 | +12296.5% | 0.00% | – |
| Q4 2016 | $2,000 | -33.3% | 430 | 0.0% | 0.00% | – |
| Q3 2016 | $3,000 | 0.0% | 430 | 0.0% | 0.00% | – |
| Q2 2016 | $3,000 | -75.0% | 430 | -73.6% | 0.00% | – |
| Q1 2016 | $12,000 | -89.5% | 1,630 | -84.6% | 0.00% | – |
| Q4 2015 | $114,000 | +1325.0% | 10,585 | +782.1% | 0.00% | – |
| Q3 2015 | $8,000 | -57.9% | 1,200 | -51.2% | 0.00% | – |
| Q2 2014 | $19,000 | – | 2,460 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 12,033,220 | $92,896,000 | 11.87% |
| RTW INVESTMENTS, LP | 2,558,859 | $19,754,000 | 7.17% |
| TURNER INVESTMENTS LLC | 859,560 | $6,636,000 | 1.80% |
| DAFNA Capital Management LLC | 236,500 | $1,826,000 | 1.58% |
| Ghost Tree Capital, LLC | 250,000 | $1,930,000 | 1.09% |
| Orbimed Advisors | 11,519,700 | $88,932,000 | 0.94% |
| Rock Springs Capital Management LP | 1,220,000 | $9,418,000 | 0.79% |
| Opus Point Partners Management, LLC | 99,000 | $764,000 | 0.59% |
| Bellevue Group AG | 420,000 | $3,242,000 | 0.59% |
| Cormorant Asset Management, LP | 500,000 | $3,860,000 | 0.58% |